Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications

Tang, Bihua; Wang, Ya‐Ting; Ren, Jie

doi:10.1002/ibra.12098

Cited by 15 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choice of ligands. caffeine [18], Curcumin [19], Nicotine [20], and Memantine [21] were selected as ligands based on previous research indicating their potential efficacy against Alzheimer's disease. These ligands were retrieved from NCBI and converted from SDF to PDB format using the Online Smiles Converter.…”

Section: Methodsmentioning

confidence: 99%

Targeting beta-amyloid plaques and neurofibrillary tangles: a proteomic approach towards Alzheimer’s disease therapy

Kashif,

Feroze,

Sethi

2024

IJBCh

View full text Add to dashboard Cite

Alzheimer’s disease (AD) stands as the most prevalent form of dementia affecting elderly individuals and ranks as the sixth leading cause of death globally. The pathological hallmarks of AD involve the formation of beta-amyloid plaques and neurofibrillary tangles in the brains of affected individuals, contributing to progressive brain degradation. This study aimed to utilize molecular modeling methods as a theoretical approach to explore the inhibition of beta-amyloid plaques and neurofibrillary tangles. Beta-amyloid and tau receptors were employed to carry out molecular docking with the ligands, including curcumin, memantine, nicotine, and caffeine. The selected compounds demonstrated minimum binding affinity and interactions with the active sites of the receptors while docking studies were performed. Notably, molecular interactions of the receptor complexes with curcumin compounds exhibited prominence in number. Curcumin, known for its antioxidant, anti-inflammatory, and lipophilic properties, has shown promise in enhancing cognitive function in AD patients. The findings of this study highlight the potential for further research aimed at developing improved drugs based on curcumin for the treatment of AD.

show abstract

Section: Methodsmentioning

confidence: 99%

Targeting beta-amyloid plaques and neurofibrillary tangles: a proteomic approach towards Alzheimer’s disease therapy

Kashif,

Feroze,

Sethi

2024

IJBCh

View full text Add to dashboard Cite

show abstract

“…The FDA has approved memantine to treat moderate and severe AD alone or combined with AChEIs. Studies indicated that memantine alone can benefit patients with moderate to severe AD, enhancing daily activities and cognitive function [ 32 ]. An advantage of memantine is its compatibility with AChEIs, as they work differently and complement each other’s effects without increasing side effects.…”

Section: Current Treatments and Their Limitationsmentioning

confidence: 99%

Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications

Sivamaruthi,

Kapoor,

Kukkar

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Globally, many individuals struggle with Alzheimer’s disease (AD), an unrelenting and incapacitating neurodegenerative condition. Despite notable research endeavors, effective remedies for AD remain constrained, prompting the exploration of innovative therapeutic avenues. Within this context, silica-based nanoplatforms have emerged with pronounced potential due to their unique attributes like expansive surface area, customizable pore dimensions, and compatibility with living systems. These nanoplatforms hold promise as prospective interventions for AD. This assessment provides a comprehensive overview encompassing various forms of mesoporous silica nanoparticles (MSNs), techniques for formulation, and their applications in biomedicine. A significant feature lies in their ability to precisely guide and control the transport of therapeutic agents to the brain, facilitated by the adaptability of these nanoplatforms as drug carriers. Their utility as tools for early detection and monitoring of AD is investigated. Challenges and prospects associated with harnessing MSNs are studied, underscoring the imperative of stringent safety evaluations and optimization of how they interact with the body. Additionally, the incorporation of multifunctional attributes like imaging and targeting components is emphasized to enhance their efficacy within the intricate milieu of AD. As the battle against the profound repercussions of AD persists, MSNs emerge as a promising avenue with the potential to propel the development of viable therapeutic interventions.

show abstract

“…They are utilized to alleviate cognitive impairment and slow down the progression of dementia in AD patients [ 15 ]. Memantine, an NMDA receptor antagonist, has been approved for moderate-to-severe AD [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence

Azargoonjahromi,

Abutalebian

2024

Nutr Metab (Lond)

View full text Add to dashboard Cite

Context Resveratrol (RV), a natural compound found in grapes, berries, and peanuts, has been extensively studied for its potential in treating Alzheimer’s disease (AD). RV has shown promise in inhibiting the formation of beta-amyloid plaques (Aβ) and neurofibrillary tangles (NFTs), protecting against neuronal damage and oxidative stress, reducing inflammation, promoting neuroprotection, and improving the function of the blood–brain barrier (BBB). However, conflicting results have been reported, necessitating a comprehensive umbrella review of systematic reviews to provide an unbiased conclusion on the therapeutic effectiveness of RV in AD. Objective The objective of this study was to systematically synthesize and evaluate systematic and meta-analysis reviews investigating the role of RV in AD using data from both human and animal studies. Data sources and extraction Of the 34 systematic and meta-analysis reviews examining the association between RV and AD that were collected, six were included in this study based on specific selection criteria. To identify pertinent studies, a comprehensive search was conducted in English-language peer-reviewed journals without any restrictions on the publication date until October 15, 2023. The search was carried out across multiple databases, including Embase, MEDLINE (PubMed), Cochrane Library, Web of Science, and Google Scholar, utilizing appropriate terms relevant to the specific research field. The AMSTAR-2 and ROBIS tools were also used to evaluate the quality and risk of bias of the included systematic reviews, respectively. Two researchers independently extracted and analyzed the data, resolving any discrepancies through consensus. Of note, the study adhered to the PRIOR checklist. Data analysis This umbrella review presented robust evidence supporting the positive impacts of RV in AD, irrespective of the specific mechanisms involved. It indeed indicated that all six systematic and meta-analysis reviews unanimously concluded that the consumption of RV can be effective in the treatment of AD. Conclusion RV exhibits promising potential for benefiting individuals with AD through various mechanisms. It has been observed to enhance cognitive function, reduce Aβ accumulation, provide neuroprotection, protect the BBB, support mitochondrial function, facilitate synaptic plasticity, stabilize tau proteins, mitigate oxidative stress, and reduce neuroinflammation commonly associated with AD. Graphical abstract

show abstract

Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications

Cited by 15 publications

References 49 publications

Targeting beta-amyloid plaques and neurofibrillary tangles: a proteomic approach towards Alzheimer’s disease therapy

Targeting beta-amyloid plaques and neurofibrillary tangles: a proteomic approach towards Alzheimer’s disease therapy

Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications

Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence

Contact Info

Product

Resources

About